XML 19 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Changes in Stockholders' Deficit - USD ($)
$ in Thousands
Previously Reported [Member]
Common Stock [Member]
Previously Reported [Member]
Additional Paid-in Capital [Member]
Previously Reported [Member]
Retained Earnings [Member]
Previously Reported [Member]
AOCI Attributable to Parent [Member]
Previously Reported [Member]
Revision of Prior Period, Error Correction, Adjustment [Member]
Common Stock [Member]
Revision of Prior Period, Error Correction, Adjustment [Member]
Additional Paid-in Capital [Member]
Revision of Prior Period, Error Correction, Adjustment [Member]
Retained Earnings [Member]
Revision of Prior Period, Error Correction, Adjustment [Member]
AOCI Attributable to Parent [Member]
Revision of Prior Period, Error Correction, Adjustment [Member]
Revision of Prior Period, Reclassification, Adjustment [Member]
Common Stock [Member]
Revision of Prior Period, Reclassification, Adjustment [Member]
Additional Paid-in Capital [Member]
Revision of Prior Period, Reclassification, Adjustment [Member]
Retained Earnings [Member]
Revision of Prior Period, Reclassification, Adjustment [Member]
AOCI Attributable to Parent [Member]
Revision of Prior Period, Reclassification, Adjustment [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance at Dec. 31, 2021 [1]                     $ (6) $ 6          
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 2)                     3,685 3,685          
Issuance of common stock upon conversion of MURF Class A & Class B common stock in connection with merger (Note 2)                     1 (15,219) (15,218)          
Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing (Note 2)                     19,779 19,779          
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC                     151 151          
Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC                     544 544          
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 2)                              
Reduction of excise tax liability associated with the Merger (Note2)                     1,141     1,141          
Capital contribution - related party                     150 150          
Stock-based compensation                     199 199          
Foreign currency translation adjustment                       (264) (264)          
Net loss                     (535) (535)          
Balance at Dec. 31, 2022 $ (10,764) $ 675 $ (10,089) $ 6 $ (6) [2] $ 6 [2] $ (6) [2] [2] [2] $ 6 [3] [3] $ (10,770) [3] $ 675 [3] $ (10,089) [3]
Balance, shares at Dec. 31, 2022 20         646,244                   646,264 [3]        
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares                               3,735        
Issuance of common stock upon conversion of MURF Class A & Class B common stock in connection with merger, shares                               41,183        
Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing, shares                               20,000        
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC, shares                               3,955        
Issuance of Conduit Pharmaceuticals Inc. common stock to Vela Technologies PLC, shares                               10,158        
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger, shares                               13,000        
Net loss                                       (535)
Issuance of Common Stock upon Exercise of Conversion Option                                      
Balance at Dec. 31, 2023                               $ 7 10,424 (11,299) 411 (457)
Balance, shares at Dec. 31, 2023                               738,295        
Foreign currency translation adjustment                               3 3
Net loss                               (17,802) (17,802)
Correction of immaterial error related to franchise tax expense                               144     144
Issuance of Common Stock for services                               242 242
Issuance of Common Stock for services, shares                               19,500        
Issuance of Common Stock upon vesting of restricted stock units                              
Issuance of Common Stock upon vesting of restricted stock units, shares                               745        
Issuance of Common Stock for note payable                               $ 2 995 997
Issuance of Common Stock for note payable, shares                               95,045        
Issuance of Common Stock for licensing right                               $ 1 1,567 1,568
Issuance of Common Stock for licensing right, shares                               125,000        
Issuance of Common Stock under the ATM Program                               $ 3 3,218 3,221
Issuance of Common Stock under the ATM Program, shares                               323,273        
Issuance of Common Stock in Exchange for Debt Modification                               $ 1 488 489
Issuance of Common Stock in Exchange for Debt Modification, shares                               39,193        
Issuance of Common Stock upon Exercise of Conversion Option                               92 92
Issuance of Common Stock upon Exercise of Conversion Option, shares                               23,000        
Issuance of Warrants                               2,890 2,890
Issuance of Common Stock Upon Exercise of Warrants                               188 188
Issuance of Common Stock Upon Exercise of Warrants, shares                               20,000        
Stock-based compensation                               1,632 1,632
Issuance of Common Stock Upon Exercise of Warrants, shares                               750        
Balance at Dec. 31, 2024                               $ 14 $ 21,880 $ (29,101) $ 414 $ (6,793)
Balance, shares at Dec. 31, 2024                               1,384,801        
[1] Reclassification is made as the impact of the retroactive application of the Merger can be shown as a reduction to additional paid-in capital during the period as presenting the reduction does not result in additional paid-in capital being presented as a negative for its ending balance.
[2] Reclassification is made as additional paid-in capital cannot be presented as a negative for either its beginning or ending balance.
[3] Shares of legacy common stock have been retroactively restated to give effect to the Merger.